Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-09
2011-12-20
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S375000, C514S563000
Reexamination Certificate
active
08080567
ABSTRACT:
A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5is an optionally substituted C5-20aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where RP6is selected from fluoro and chloro; and R2is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.
REFERENCES:
patent: 5576347 (1996-11-01), Sredni et al.
patent: 5939332 (1999-08-01), Lee et al.
patent: 6562868 (2003-05-01), Stjernschantz et al.
patent: 7326732 (2008-02-01), Oxford et al.
patent: 7662839 (2010-02-01), Oxford et al.
patent: 2005/0209336 (2005-09-01), Borman et al.
patent: 2009/0298899 (2009-12-01), Oxford et al.
patent: 2293101 (1996-03-01), None
patent: 98/27976 (1998-07-01), None
patent: 98/34916 (1998-08-01), None
patent: 00/27823 (2000-05-01), None
patent: 00/31084 (2000-06-01), None
patent: 00/40248 (2000-07-01), None
patent: 01/46140 (2001-06-01), None
patent: 01/85167 (2001-11-01), None
patent: 02/24647 (2002-03-01), None
patent: 03/032972 (2003-04-01), None
patent: 03/037433 (2003-05-01), None
patent: 03/040126 (2003-05-01), None
patent: 03/045371 (2003-06-01), None
patent: 2004007439 (2004-01-01), None
patent: 2004/012656 (2004-02-01), None
patent: 2005/037812 (2005-04-01), None
patent: 2005/061449 (2005-07-01), None
patent: 2005/080367 (2005-09-01), None
Han (Advances in Characterization of Pharmaceutical Hydrates. Trends in Bio/Pharmaceutical Industry, pp. 25-29. Mar. 2006).
Vippagunta et al (Adv Drug Deliv Rev 48:3-26, 2001).
Anderson (Chem and Biol 10:787-797, 2003).
Thiel (Nature Biotechnol 2:513-519, 2004).
Tani et al (Bioorg Med Chem 10:1093-1106, 2002).
Berge, Stephen M., et al.; “Pharmaceutical Salts”; Journal of Pharmaceutical Sciences, vol. 66, No. 1; pp. 1-19 (Jan. 1977).
Griffiths, Christopher E.M., “T-Cell-Targeted Biologicals for Psoriasis”; Current Drugs Targets—Inflammation & Allergy; 3, pp. 157-161 (2004).
Lebwohl, Mark; “Psoriasis”; Seminar, The Lancet, vol. 361; pp. 1197-1204 (Apr. 5, 2003) (www.thelancet.com).
Nataraj, Chandra, et. al.; “Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse”; J. Clin. Invest.; 108; pp. 1229-1235 (2001) (doi: 10.1172/JCI2001 113640).
Salim, Asad & Emerson, Russell; “Targeting interleukin-2 as a treatment for psoriasis”; Current Opinion in Investigational Drugs; vol. 2, No. 11, (2001); pp. 1546-1548.
Tilley, Stephen L., et. al.; “Receptors and pathways mediating the effects of prostaglandin E2 on airway tone”; American Journal of Physiology Lung Cellular and Molecular Physiology; AJP—Lung 284: pp. 599-606 (2003); (doi: 10.1152/ajplung.00324.2002).
Useato, Shinichi, et. al.; “Novel Histone Deacetylase Inhibitors: N-Hydroxycarboxamides Possessing a Terminal Bicyclic Aryl Group”; Bioorganic and Medicinal Chemistry Letters 12 (2002); pp. 1347-1349.
Coleman, Robert A., et al.; “Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes”; International Union of Pharmacology, Pharmacological Reviews, vol. 46, No. 2, pp. 205-229; The American Society for Pharmacology and Experimental Therapeutics (1994).
Chemical Abstract Accession No. 2003:31915608; Otava Stock Chemicals Catalogue, Oct. 26, 2003, compound with CAS Registry No. 620545-88-3.
Chemical Abstract Accession No. 2003:3848742; Akos Sample Catalogue Feb. 9, 2004, compound with CAS Registry No. 618413-90-4.
Chemical Abstract Accession No. 2003:3849399; Akos Sample Catalogue, Feb. 9, 2004, compound with CAS Registry No. 618404-52-7.
Chemical Abstract Accession No. 2003:3849331; Akos Sample Catalogue, Feb. 9, 2004, compound with CAS Registry No. 618401-55-1.
Morissette, et al. Advanced Drug Delivery Reviews 2004, vol. 56, pp. 275-3000.
Patani, George A., Bioisosterism: A rational Approach in Drug Design. Chem. Rev. 96, 1996, pp. 3147-3176.
Youssefyeh, Raymond D., Development of a Novel Series of (2-Quinolinylmethoxy)phenyl-Containing Compounds as High-Affinity Leukotriene Receptor Antagonists. 1. Initial Structure-Activity Relationships. J. Med. Chem. 33 (1990) 1186-1194.
Ashton Mark Richard
Boyd Edward Andrew
Brunton Shirley Ann
Clark David Edward
Clark Kenneth Lyle
Asterand UK Limited
Bott Cynthia M.
Fetterolf Brandon
Honigman Miller Schwartz & Cohn LLP
Ricci Craig
LandOfFree
EP 2 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EP 2 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP 2 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266813